NCT00573989 · OUTCOME

Overall Survival

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer · Source last updated 2019-01-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 1 and 2 years

What was measured

Overall survival of participants reported after 2 years.

Analysis population: Data corresponds to Phase II patients.

Groups in this outcome

Erlotinib

Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Erlotinib	12

Reported measurements

1 year

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib	9	Not reported	Not reported	Not reported	Not reported

2 years

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib	7	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
9
title
1 year
categories
measurements
group Id
OG000
value
7
title
2 years

denoms

counts
group Id
OG000
value
12
units
Participants

description

Overall survival of participants reported after 2 years.

groups

description
Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy
id
OG000
title
Erlotinib

param Type

COUNT_OF_PARTICIPANTS

population Description

Data corresponds to Phase II patients.

reporting Status

POSTED

time Frame

1 and 2 years

title

Overall Survival

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice